# Judge — L4-TICK30 iter1

**Loop:** L4-TICK30 · **File:** `src/content/comparisons/cagrilintide-vs-semaglutide.mdx`
**Judge:** independent (did not write the increment). **Date of all re-fetches:** 2026-09-02.
**Implementer note:** `.planning/seo-engine/runs/2026-09-01/TICK30.md` (explicitly "not a KEEP"; no self-stamp found. No prior judge file existed.)

## Independent fetches (commands actually run, 2026-09-02)

| # | Command | Result |
|---|---------|--------|
| 1 | `curl.exe -s "https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=34798060&rettype=abstract&retmode=text"` | Lau, Lancet 2021;398:2160-72. Title topical-matches cagrilintide. |
| 2 | same efetch, `id=40544433` | REDEFINE 1, NEJM 2025;393:635-47. Title names both drugs. NCT05567796. |
| 3 | same efetch, `id=33567185` | STEP 1, NEJM 2021;384:989-1002. NCT03548935. |
| 4 | same efetch, `id=37952131` | SELECT, NEJM 2023;389:2221-32. NCT03574597. |
| 5 | `curl.exe -s "https://clinicaltrials.gov/api/v2/studies/NCT06131437"` | `hasResults:false`, `overallStatus:COMPLETED`, enrollment 809 ACTUAL, primaryCompletion 2025-12-08 ACTUAL, acronym null. Title matches page source title verbatim. |
| 6 | `curl.exe -s ".../esearch.fcgi?db=pubmed&term=NCT06131437&retmode=json"` | `count:"0"` — page's dated absence claim is true. |
| 7 | `curl.exe ... api.fda.gov/drug/drugsfda.json?search=openfda.generic_name:"cagrilintide"` | HTTP 404 — page's dated NOT_FOUND claim is true. |
| 8 | `curl.exe ... drugsfda.json?search=application_number:"NDA…"` for 209637 / 215256 / 218316 / 213051 | 209637 → OZEMPIC SOLUTION SUBCUTANEOUS; 215256 → WEGOVY SOLUTION SC; 218316 → WEGOVY TABLET ORAL. All three page claims verified. (213051 → see Observations.) |
| 9 | `node scripts/qa-medical-advice.mjs --strict` | exit 0, "PASS: no instructional voice found." |
| 10 | `node scripts/qa-claim-consistency.mjs` | exit 0. Near-miss note on this file for "95%" — those are "95% CI" strings, benign. |
| 11 | `git diff HEAD -- <file>` | 100 insertions / 107 deletions; removed lines include the ticketed defects (below). |
| 12 | `Test-Path` on all 4 link targets + Select-String battery on the live file | All targets exist; banned strings absent. |

## Fail-condition checklist (from the brief)

| # | Condition | Verdict | Evidence |
|---|-----------|---------|----------|
| 1 | Census FAQ (34/27 vs 67/52) still live | **PASS** (gone) | Diff removed lines: `- Cagrilintide has 34 sources (27 human studies), rated High evidence.` / `- Semaglutide has 67 sources (52 human studies), rated High evidence.` Live FAQ now states "This page does not quote a live source census." |
| 2 | ~6/~9/~11 or CagriSema ~15–24% hedges as data | **PASS** (gone) | Diff removed `-| 1.2mg | ~6% |`, `-| 2.4mg | ~9% |`, `-| 4.5mg | ~11% |`, `-| Cagrilintide alone | ~11% |`. Select-String for `~6|~9|~11|~15` on live file: 0 hits. |
| 3 | REDEFINE 22.7 / 15.7 / 23–25.5 | **PASS** (absent) | Select-String `22.7|15.7|25.5`: 0 hits. REDEFINE 1 abstract (fetch #2) does not contain them either; page quotes only −20.4% vs −3.0% (ETD −17.3; CI −18.1 to −16.6; P<0.001) — exact match to abstract. |
| 4 | Unpublished REDEFINE 4 percents | **PASS** | Page quotes zero efficacy numbers for NCT06131437; states COMPLETED / hasResults false / 809 actual / 2025-12-08 — all verified by fetch #5. Dated PubMed esearch absence verified by fetch #6. |
| 5 | Lau range mislabelled treatment-policy | **PASS** | Fetch #1 abstract: "According to the **trial product estimand**, mean percentage weight reductions … (0·3-4·5 mg, 6·0%-10·8%) versus placebo (3·0%…; p<0·001). … Similar weight loss reductions were observed with the treatment policy estimand." Page labels the 6.0–10.8% vs 3.0% range **trial-product** and says treatment-policy was "similar" with no second table — exactly the abstract. Estimand label is correct, not swapped. |
| 6 | Unresolved PMIDs/NCTs | **PASS** | All 5 on-page identifiers re-fetched and topical-matched today (fetches #1–5). No sibling-trial mixup: 40544433 is REDEFINE 1 (NCT05567796), not REDEFINE 2 (40544432, not cited). |
| 7 | Trailing-slash compare links | **PASS** | Live links: `/peptides/cagrilintide`, `/peptides/semaglutide`, `/compare/cagrisema-vs-tirzepatide`, `/compare/cagrilintide-vs-tirzepatide` — no trailing slash; all 4 targets confirmed on disk via `Test-Path` (Glob index was flaky on OneDrive; filesystem is authoritative). |
| 8 | Dosing / purchasing / medical advice | **PASS** | `qa:advice --strict` exit 0. Manual battery (buy/purchase/inject/stack/cycle/vendor/reconstitute): 0 hits. Page explicitly: "not a recommendation to combine products outside a protocol. This page does not recommend a regimen." |
| 9 | Implementer stamped own KEEP | **PASS** | TICK30.md header: "implementer note (not a KEEP)"; "Did not mark KEEP." No judge file existed before this one. |

## L4 judge-bar extras (LOOPS.md)

- **Absence claims window-dated:** all three (PubMed 0-record, openFDA NOT_FOUND, hasResults false) carry "on 2026-09-02". PASS.
- **Efficacy estimand not headlined:** Lau trial-product is labelled as such; STEP 1 leads with the primary (ITT-type) estimand described verbatim from the abstract; REDEFINE 1 labelled treatment-policy per abstract. PASS. (Note: STEP 1's abstract describes but does not name the estimand; the page's "treatment-regimen" tag is engine vocabulary per ORCHESTRATOR §1.5 attached to the verbatim description — acceptable.)
- **No fuzzy auto-attach; no new identifiers beyond fetched ones.** PASS.
- **Schema:** frontmatter validates against `comparisons` in `src/content/config.ts` (sources[] id/title/url/type/pmid/nctId/verifiedAt; types `journal`/`trial` in enum; category `metabolic` valid). Body citation ids `[lau-pmid-34798060] [step-1-pmid-33567185] [select-pmid-37952131] [redefine-1-pmid-40544433] [redefine-4-nct-06131437]` all resolve to sources[] entries — no dangling ids.
- **Number spot-checks vs fetches:** STEP 1 −14.9/−2.4, ETD −12.4 (CI −13.4 to −11.5), ≥10% 69.1/12.0, ≥15% 50.5/4.9, GI d/c 4.5/0.8 — all exact. SELECT 569/8803 (6.5%) vs 701/8801 (8.0%), HR 0.80 (0.72–0.90), 39.8 mo — exact. REDEFINE 1 n=3417, 21:3:3:7, 302/302 mono arms unpublished — exact. Lau GI 41–63/32, nausea 20–47/18, 4.5 mg vs liraglutide 10.8/9.0 (ETD 1.8, P=0.03) — exact. `P&lt;` escaped throughout; no unescaped `<` in MDX.

## Observations (non-blocking)

1. **NDA213051 exists** in Drugs@FDA as of 2026-09-02 (OZEMPIC / TABLET / ORAL + RYBELSUS / TABLET / ORAL products). Every per-NDA claim on the page verified true, but the FAQ's "Ozempic (subcutaneous)" enumeration omits the oral Ozempic application. Completeness gap, not a fabrication; not on this loop's fail list. Conductor may queue a one-line freshness touch.
2. `qa:claims` near-miss flag on "95%" for this file = "95% CI" strings; benign, exit 0.
3. Recurring "This page does not invent X" sentences are defensive but each maps to a real defect class removed in this diff; cosmetic, not an integrity issue.

## Gaming check

The increment is substantive (100+/107−), not a strip-to-empty: four trial programmes carry verified numbers with placebo arms and harms included, so there is no favorable-arm cherry-picking. The diff removes exactly the ticketed defect classes (census FAQ, invented per-dose rows, half-life table, 2025–2026 timeline, tirzepatide-superiority language), confirming the work is real rather than cosmetic. The implementer declined to self-KEEP, stayed inside the assigned file, and did not touch locked compares or dossiers. The one omission found (NDA213051) is a completeness gap in an enumeration whose every stated member is accurate — it hides nothing the brief required, and the page's specific claims all survived adversarial re-fetch. No net-URL change, no link-graph risk, no banned content.

## Verdict

**KEEP.**

Fail conditions 1–9 all PASS against independent fetches recorded above. L4 estimand, sibling-trial, windowed-absence, and dangling-id bars all pass. Observation 1 is forwarded to the Conductor as a possible future one-liner; it does not block this loop.
